Söndag 8 Juni | 06:29:11 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-25 08:00 Bokslutskommuniké 2025
2025-11-26 08:00 Kvartalsrapport 2025-Q3
2025-08-27 08:00 Kvartalsrapport 2025-Q2
2025-05-21 - X-dag ordinarie utdelning MODTX 0.00 SEK
2025-05-20 - Årsstämma
2025-05-14 - Kvartalsrapport 2025-Q1
2025-02-20 - Bokslutskommuniké 2024
2024-11-20 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-20 - X-dag ordinarie utdelning MODTX 0.00 SEK
2024-05-17 - Årsstämma
2024-05-14 - Kvartalsrapport 2024-Q1
2024-02-21 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning MODTX 0.00 SEK
2023-05-11 - Årsstämma
2023-05-09 - Kvartalsrapport 2023-Q1
2023-02-22 - Bokslutskommuniké 2022
2022-11-22 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-05-16 - Kvartalsrapport 2022-Q1
2022-05-12 - X-dag ordinarie utdelning MODTX 0.00 SEK
2022-05-11 - Årsstämma
2022-02-22 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Modus Therapeutics är verksamt inom bioteknik. Produktportföljen är bred och inkluderar exempelvis sevuparin. Bolagets fokus är att utveckla sevuparin för patienter med sepsis / septisk chock, ett allvarligt och ofta dödligt tillstånd. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten med tillhörande forskning drivs med störst närvaro inom Sverige.
2025-05-14 15:45:00

Stockholm, Sweden – May 14, 2025 — Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with significant unmet medical needs, today announces that the company has been selected to present a poster at the European Hematology Association (EHA) Congress 2025 in Milan, Italy. The presentation will highlight new preclinical data on the investigational drug sevuparin in a model of chronic kidney disease (CKD).

The abstract, titled “Improvement of Anemia and Kidney Status by Sevuparin Treatment in a Mouse Model of Chronic Kidney Disease,” describes results from studies conducted in collaboration with researchers at the University of Brescia led by Professor Maura Poli and senior scientist Michela Asperti. The data show that sevuparin, a low-anticoagulant heparinoid compound, significantly improved anemia and kidney status along with a reduction of known fibrosis and damage markers in the kidney tissue from a CKD mouse model, both as a monotherapy and in combination with erythropoietin (EPO).

Key findings include:

  • Reduced gene expression of known markers of kidney fibrosis and damage
  • Increased hemoglobin and hematocrit levels following sevuparin treatment along with reduced serum hepcidin levels
  • The effects were present with sevuparin monotherapy and in combination with EPO

“These results provide further support for the therapeutic potential of sevuparin in treating anemia in chronic inflammation such as kidney disease and offer new insights into its protective effects on kidney function,” said John Öhd, CEO of Modus Therapeutics. “The data are highly relevant to our ongoing Phase IIa clinical study in CKD-related anemia.”

The poster will be presented during Poster Session 2 on Saturday, June 14, 2025 (18:30–19:30 CEST) at the MiCo Convention Center in Milan.
The abstract is available via the EHA2025 Congress platform:
EHA2025 Congress